Coronavirus Update: Oxford Racing Ahead With 8,000 Vaccinated In Phase III Trial
Plus: Eisai Joins RE-MAP Cap Study
Partnering with AstraZeneca, the Oxford team has opened up a clear lead in the race to enrol thousands of patients for late-stage safety and efficacy trials – but cannot make guarantees of when results might be ready.
